1. Home
  2. Live Updates
  3. Montreal hospital center

Live Breaking News & Updates on Montreal hospital center

Stay informed with the latest breaking news from Montreal hospital center on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Montreal hospital center and stay connected to the pulse of your community

Quebec adds more virtual wards to increase at-home medical care - Montreal

The program allows people who have been hospitalized to go home sooner while still receiving care. Experts say it's a step in the right direction but not a one-stop solution.

Montreal , Quebec , Canada , Eveline-gaillardetz , Paul-brunet , Erin-cook , Gloria-henirquez , University-of-montreal-hospital-center , Mcgill-university-health-centre , Jewish-general-hospital , Gill-university-health-centre , Montreal-hospital-center

Automated Processing, EEG Algorithm Predicts 1-Year Seizure Recurrence in Patients

Predictions for identifying 1-year seizure recurrence performed significantly better in electroencephalography (EEG) without interictal epileptiform discharges.


Montreal , Quebec , Canada , University-of-montreal-hospital-center , Montreal-hospital-center ,

Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC

Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.

Canada , United-states , Montreal , Quebec , American , Fred-saad , Raymond-garneau , Montreal-cancer-institute , University-of-montreal-hospital-center , American-urological-association , University-of-montreal , Research-center

Dr Saad on PSA Response and Time to PSA Progression With Abiraterone Acetate and Olaparib in mCRPC

Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.

Montreal , Quebec , Canada , Raymond-garneau , Fred-saad , Department-of-surgery , Montreal-cancer-institute , University-of-montreal-hospital-center , University-of-montreal , Research-center , Prostate-cancer-working-group , Montreal-hospital-center

Electrocochleography Can Predict Symptom Improvement in Vestibular Migraine

Use of diagnostic criteria for vestibular migraine (VM) combined with the area-under-the-curve ratio of the summating potentials and action potentials curves on electrocochleography (ECoG) is better for predicting symptom improvement than diagnostic criteria alone.

Montreal , Quebec , Canada , Paul-tabet , Audiology-research , University-of-montreal-hospital-center , Healthday-news , Montreal-hospital-center ,

Olaparib Prolongs rPFS in Metastatic Castration-Resistant Prostate Cancer

Adding olaparib to first-line abiraterone improved radiographic progression-free survival in metastatic castration-resistant prostate cancer.

Montreal , Quebec , Canada , Fred-saad , Astrazeneca , University-of-montreal-hospital-center , Merck-sharp-dohme-corp , Montreal-hospital-center , Cancers-symposium , Merck-sharp ,

PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer

Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.

Montreal , Quebec , Canada , United-kingdom , Vancouver , British-columbia , British , Fred-saab , Kimn-chi , University-of-british-columbia , Department-of-urologic-sciences , Vancouver-prostate-center

Olaparib Prolongs rPFS in Metastatic Castration-Resistant Prostate Cancer

Adding olaparib to first-line abiraterone improved radiographic progression-free survival in metastatic castration-resistant prostate cancer.

Montreal , Quebec , Canada , Fred-saad , Astrazeneca , University-of-montreal-hospital-center , Merck-sharp-dohme-corp , Cancers-symposium , Cancer-therapy-advisor , Montreal-hospital-center , Merck-sharp ,

Olaparib regimen benefits men with metastatic castration-resistant prostate cancer

SAN FRANCISCO  — The addition of olaparib to abiraterone acetate significantly extended radiographic PFS as first-line treatment for metastatic castration-resistant prostate cancer, according to an interim analysis of the randomized phase 3 PROpel study.
The findings, presented at ASCO Genitourinary Cancers Symposium, showed men experienced the benefit regardless of homologous

Montreal , Quebec , Canada , San-francisco , California , United-states , Devin-mclaughlin , Fred-saad , Astellas-pharma , Pfizer , Astrazeneca , Myovant-sciences

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza combo delays progression risk in prostate

Investegate announcements from AstraZeneca PLC, Lynparza combo delays progression risk in prostate

Japan , United-states , United-kingdom , China , Montreal , Quebec , Canada , Kenilworth , Warwickshire , Cambridge , Cambridgeshire , American